An anti-cancer agent that selectively acts on CDK1 among the cyclin-dependent kinases (CDKs) that regulates the cell cycle
BEY1107G induces apoptosis through cell suicide mechanism by synchronizing the G2 / M cell cycle phases of the glioblastoma. In addition, BEY1107G inhibits the self renewal of cancer stem cells, demonstrating its effectiveness as a monotherapy.
When used in combination with Temozolomide a treatment for glioblastoma, it shows improved anti-cancer treatment effects. It is expected to overcome resistance and recurrence of cancer which is evident when Temozolomide is administered as a monotherapy.
Currently, BEY1107 is in phase I clnical trial and aims to enter into phase II clinical trial in the second half of 2019.